General Catalyst

Activity from announced rounds

Activity in this selectionJan 31, 2026 · Jan 1, 2026

General Catalyst backs companies from formation and seed through growth, and also creates businesses with founders through its Creation strategy.

Creation includes starting companies in complex or emerging industries, helping experienced founders launch again and combining existing service businesses with applied AI. That makes GC relevant both to founders raising for an established startup and to entrepreneurs developing a new company with an investment partner.

For businesses that have reached product-market fit, its Customer Value Fund provides a separate way to finance customer acquisition. This sits alongside seed and growth equity, giving the firm a financing model directed specifically at the cost of expanding a customer base.

Sources
Rounds participated in
8
Confirmed lead rounds
—
8 roles undisclosed
New companies
8
First participation on record · 0 follow-on
Funding in participating rounds
$1.1B
8 disclosed · full round size, not this investor’s share

By stage

Series A3
Series C+3
Pre-seed1
Series B1

By primary sector

AI2
Defense tech2
Biotech1
Enterprise software1
Healthtech1
1 more
Media & gaming1

By country

United States4
Germany2
Sweden1
Turkey1

Rounds

8 in this selection
Stilla

Develops collaborative intelligence for AI-driven companies

$5MPre-Seed
Role not disclosed
Orbem

Applies AI to magnetic resonance imaging for non-invasive analysis of biological materials

€55.5MSeries B
Role not disclosed
TaleMonster Games

Develops casual mobile games with puzzle and strategy elements

$30MSeries A
Role not disclosed
Parloa

Provides AI agents for enterprise customer experience

$350MSeries D
Role not disclosed
Onebrief

AI-powered platform for military command and operations

$200MSeries D
Role not disclosed
Valinor Enterprises

Builds and buys critical defense and government technology solutions

$54MSeries A
Role not disclosed
Parabilis Medicines

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries F
Role not disclosed